Menezes J, Leibold W, Klein G, Clements G
Biomedicine. 1975 Jul;22(4):276-84.
An Epstein-Barr virus (EBV)-negative lymphoblastoid cell line (LCL), BJA-B, was established from an African Burkitt's lymphoma (BL) which contained no detectable EBV DNA and did not express the EBV specified antigen EBNA, BJA-B cells grow in typically large, flat clumps. All carry surface-bound immunoglobulins, a B lymphocyte marker, and do not form rosettes with sheep erythrocytes. After infection of BJA-B cells by EBV the infected cells may produce either EBV-determined nuclear antigen (EBNA) or both EBNA and early antigen (EA), depending on the strain of EBV. The homogeneity of the BJA-B cell population with respect to immunological and isoenzyme markers and size suggests a clonal origin of the line. BJA-B is the first EBV-negative LCL established from an African Burkitt's lymphoma and demonstrates that an EBV-independent continuous B cell line can be established "in vitro" from other than leukemia or myeloma cells.
一种爱泼斯坦-巴尔病毒（EBV）阴性的淋巴母细胞系（LCL），即BJA-B，是从一名非洲伯基特淋巴瘤（BL）患者身上建立的，该肿瘤中未检测到EBV DNA，也不表达EBV特异性抗原EBNA。BJA-B细胞通常以大的扁平团块形式生长。所有细胞都携带表面结合免疫球蛋白，这是一种B淋巴细胞标志物，并且不与绵羊红细胞形成玫瑰花结。用EBV感染BJA-B细胞后，根据EBV的毒株不同，被感染的细胞可能产生EBV决定的核抗原（EBNA），或者同时产生EBNA和早期抗原（EA）。BJA-B细胞群体在免疫和同工酶标志物以及大小方面的同质性表明该细胞系起源于克隆。BJA-B是首个从非洲伯基特淋巴瘤建立的EBV阴性LCL，证明了可以从白血病或骨髓瘤细胞以外的细胞“体外”建立不依赖EBV的连续B细胞系。
